0000950170-23-053752.txt : 20231017 0000950170-23-053752.hdr.sgml : 20231017 20231017161508 ACCESSION NUMBER: 0000950170-23-053752 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231012 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20231017 DATE AS OF CHANGE: 20231017 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 231329758 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 8-K 1 inkt-20231012.htm 8-K 8-K
0001840229false00018402292023-10-122023-10-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 12, 2023

 

 

MiNK Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40908

82-2142067

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

149 Fifth Avenue

Suite 500

 

New York, New York

 

10010

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 212 994-8250

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.00001 per share

 

INKT

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 12, 2023, Dr. John Baldoni sent notice of his resignation as a director at MiNK Therapeutics, Inc. (the "Company"), effective October 31, 2023. Dr. Baldoni cited the Company’s manufacturing advancements and progress, thereby lessening the need for his scientific and technical contributions on the Board of Directors. Dr. Baldoni will advise the Company on an ad hoc basis as a technical advisor. Dr. Baldoni did not step down as a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

October 17, 2023

By:

/s/ Jennifer S. Buell, Ph.D.

 

 

 

Jennifer S. Buell, Ph.D., President and Chief Executive Officer

 

 EX-101.SCH 2 inkt-20231012.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 inkt-20231012_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 4 inkt-20231012_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Oct. 12, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 12, 2023
Entity Registrant Name MiNK Therapeutics, Inc.
Entity Central Index Key 0001840229
Entity Emerging Growth Company true
Securities Act File Number 001-40908
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-2142067
Entity Address, Address Line One 149 Fifth Avenue
Entity Address, Address Line Two Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212
Local Phone Number 994-8250
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol INKT
Security Exchange Name NASDAQ
XML 6 inkt-20231012_htm.xml IDEA: XBRL DOCUMENT 0001840229 2023-10-12 2023-10-12 0001840229 false 8-K 2023-10-12 MiNK Therapeutics, Inc. DE 001-40908 82-2142067 149 Fifth Avenue Suite 500 New York NY 10010 212 994-8250 false false false false Common Stock, par value $0.00001 per share INKT NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports inkt-20231012.htm inkt-20231012.xsd inkt-20231012_lab.xml inkt-20231012_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "inkt-20231012.htm": { "nsprefix": "inkt", "nsuri": "http://minktherapeutics.com/20231012", "dts": { "inline": { "local": [ "inkt-20231012.htm" ] }, "schema": { "local": [ "inkt-20231012.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inkt-20231012_lab.xml" ] }, "presentationLink": { "local": [ "inkt-20231012_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_ffc9baee-39b3-4460-b0e3-72927410e32b", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20231012.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ffc9baee-39b3-4460-b0e3-72927410e32b", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20231012.htm", "first": true, "unique": true } } }, "tag": { "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://minktherapeutics.com/20231012/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-23-053752-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-053752-xbrl.zip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